Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
11/2003
11/13/2003US20030211113 Administering immunosuppressant
11/13/2003US20030211106 Binding tumor necrosis factor to antibody
11/13/2003US20030211100 Gene therapy; nucleic acid coding immunoglobulins; anticancer agents
11/13/2003US20030211077 Stimulanting hematopoiesis
11/13/2003US20030211075 Mixture of sensitizer and tissue factor
11/13/2003US20030211040 Phosphodiesterase activity and regulation of phosphodiesterase 1B-mediated signaling in brain
11/13/2003CA2749172A1 Re-epithelializing pharmaceutical compositions comprising xanthan gum
11/13/2003CA2736019A1 Methods and compositions for treating ectoparasite infestation
11/13/2003CA2703698A1 Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent
11/13/2003CA2491708A1 Non-viral gene delivery system
11/13/2003CA2487693A1 Method for producing preparations rich in tocotrienol
11/13/2003CA2485098A1 Use of heat shock proteins to enhance efficacy of antibody therapeutics
11/13/2003CA2485093A1 Substituted imidazole derivatives: gabaa receptor ligands
11/13/2003CA2485086A1 A combination product comprising an anti-coagulant and anti-arrhythmic oxabispidenes
11/13/2003CA2484959A1 Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same
11/13/2003CA2484797A1 Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway
11/13/2003CA2484599A1 Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
11/13/2003CA2484597A1 Thiazolidinones and the use thereof as polo-like kinase inhibitors
11/13/2003CA2484551A1 Smart pro-drugs of serine protease inhibitors
11/13/2003CA2484396A1 Method for control of depression using c terminal growth hormone (gh) fragment
11/13/2003CA2484312A1 Catechin multimers as therapeutic drug delivery agents
11/13/2003CA2484258A1 Soya cell strains with high isoflavone content
11/13/2003CA2484209A1 Protein kinase modulators and methods of use
11/13/2003CA2484189A1 Methionine aminopeptidase-2 inhibitors and methods of use thereof
11/13/2003CA2484155A1 Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein
11/13/2003CA2484095A1 Tricyclic macrolide antibacterial compounds
11/13/2003CA2484065A1 Inhibitors of histone deacetylase
11/13/2003CA2483996A1 Promoters exhibiting endothelial cell specificity and methods of using same
11/13/2003CA2483909A1 Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants
11/13/2003CA2483904A1 Use of (3-(2-ethylphenyl)-5-methoxyphenyl)-1h-[1,2,4]-triazole for the treatment of autoimmune diseases
11/13/2003CA2483843A1 Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity
11/13/2003CA2483806A1 N-acyl piperidine derivatives for use as melanocortin receptor ligands in the treatment of feeding disorders
11/13/2003CA2483785A1 Combination of cyclooxygenase-2 inhibitors and thalidomide for the treatment of neoplasia
11/13/2003CA2483573A1 Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists
11/13/2003CA2483538A1 Bicyclic 6-alkylidene-penems as .szlig.-lactamases inhibitors
11/13/2003CA2483532A1 Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them
11/13/2003CA2483529A1 Process for the preparation of 7-substituted-3-quinoline and 3-quinol-4-one carbonitriles
11/13/2003CA2482967A1 Binary or polynary targeting and uses thereof
11/13/2003CA2482784A1 Composition for treating cancer containing n,n-dimethylphytosphingosine
11/13/2003CA2477985A1 Time-resolved fluorescence assay for the detection of multimeric forms of a-.beta. or other aggregating polypeptides
11/13/2003CA2462645A1 Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
11/12/2003WO2003093219A1 NOVEL PHENYLETHANOLAMINE COMPOUNDS HAVING β2-ACCEPTOR EXCITATORY FUNCTION AND THEIR PREPARATION METHOD
11/12/2003EP1361273A2 Interleukin-3 (IL-3) multiple mutation polypeptides
11/12/2003EP1361267A2 Mesenchymal stem cells and their use
11/12/2003EP1360959A1 Use of 8-prenylflavanones for anti-angiogenesis therapy and for fibrinolytic therapy
11/12/2003EP1360486A2 Screening method for identifying compounds that selectively induce interferon alpha
11/12/2003EP1360311A2 Membrane penetrating peptides and uses thereof
11/12/2003EP1360299A2 The genome of a bifidobacterium
11/12/2003EP1360295A2 Molecules for desease detection and treatment
11/12/2003EP1360204A2 Test system for the development of therapeutic agents, in particular active compounds for the treatment of osteoporosis
11/12/2003EP1360203A1 Antibodies to non-functional p 2 x 7 receptor diagnosis and treatment of cancers and other conditions
11/12/2003EP1360189A1 Formulation of boronic acid compounds
11/12/2003EP1360185A2 Carboline derivatives
11/12/2003EP1360184A1 Piperidinee derivatives as neurokinin 1 antagonists
11/12/2003EP1360178A2 Novel heterocyclic analogs of diphenylethylene compounds
11/12/2003EP1360175A1 1g(a)-amino-n-hydroxy-acetamide derivatives
11/12/2003EP1360174A1 Phenethanolamine derivatives for treatment of respiratory diseases
11/12/2003EP1360173A2 Trisubstituted carbocyclic cyclophilin binding compounds and their use
11/12/2003EP1360172A1 Ppar agonists
11/12/2003EP1360170A1 Carboxylic amides, the production and use thereof as medicaments
11/12/2003EP1360169A2 Succinate salt of o-desmethyl-venlafaxine
11/12/2003EP1360167A1 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (adp-ribose) glycohydrolase, and methods for their use
11/12/2003EP1359932A2 Tip39 polypeptides
11/12/2003EP1359930A2 Novisprins: antimicrobial peptides
11/12/2003EP1359923A1 Use of selenite or preparations containing selenite for treating wounds
11/12/2003EP1359913A1 Thrombin inhibitors
11/12/2003EP1359905A2 Use of mglur5 antagonists for the treatment of pruritic conditions
11/12/2003EP1359904A2 P27 prevents cellular migration
11/12/2003EP1359897A2 Cosmetic composition and method for reducing or preventing wrinkling
11/12/2003EP1359885A1 Nos inhibitors for treatment of wrinkles
11/12/2003EP1359883A2 (psi)(epsilon)rack peptide composition and method for protection against tissue damage due to ischemia
11/12/2003EP1282614B1 Hydroxamic acid derivatives
11/12/2003EP1255564B1 Pharmaceutical composition comprising squalene epoxidase inhibitor and macrolide immunomodulator
11/12/2003EP1242402B1 Novel compounds
11/12/2003EP1233973B1 Partial or full a1 agonists - n6 heterocyclic 5'-thio substituted adenosine derivatives
11/12/2003EP1214062B1 Use of nicotinic acetylcholine receptor agonists for the preparation of a medicament for the treatment of dry eye disease
11/12/2003EP1206444B1 Compounds that inhibit tryptase activity
11/12/2003EP1206265B1 Src kinase inhibitor compounds
11/12/2003EP1200412B1 Imidazole antiproliferative agents
11/12/2003EP1178819B1 Glutathione reductase for therapy and prophylaxis of aids
11/12/2003EP1112083B1 Use of an angiogenic factor for the treatment of microvascular angiopathies
11/12/2003EP1094815B1 Farnesyl protein transferase inhibitors for treating arthropathies
11/12/2003EP1019373B1 1-acyl-3-phenyl-3-(3-piperidinopropyl)piperidine derivatives as human nk3 receptor selective antagonists
11/12/2003EP1011706B1 USE OF SOLUBLE RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS (sRAGE) TO PREVENT ACCELERATED ATHEROSCLEROSIS
11/12/2003EP0996618B1 Endothelin antagonists: n- 2'- (4,5-dimethyl-3-isoxazolyl) amino]sulfonyl]-4-(2-oxazolyl) 1,1'-biphenyl]-2-yl]methyl] -n,3,3-trimethylbutanamide and n-(4,5-dimethyl-3-isoxazolyl) -2'- (3,3-dimethyl-2-oxo-1-pyrrolidinyl) methyl] -4'-(2-oxazolyl) 1,1'-biphenyl]-2-sulfonamide and salts thereof
11/12/2003EP0994904B1 Amino acid sequences for therapeutical and prophylactic applications to diseases due to clostridium difficile toxins
11/12/2003EP0970379B1 Methods to identify beta-amyloid reducing agents
11/12/2003EP0861243B1 Heterocyclic compounds as bradykinin antagonists
11/12/2003EP0817623B1 Medicaments for the selective treatment of tumour tissues
11/12/2003EP0760657B1 Novel potent inducers of terminal differentiation and methods of use thereof
11/12/2003EP0752987B1 Pyrimidinyl derivatives as interleukin inhibitors
11/12/2003EP0583378B1 Combined calcium and vitamin d supplements
11/12/2003CN1455779A Clycerophosphoinositol derivatives as modulators of cytosolic phospholipase
11/12/2003CN1455771A Cyclic amine phenyl Beta-3 adrenergic receptor agonists
11/12/2003CN1455770A (2-azabicyclo [2,2,1] hept-7-yl] methanol derivatives as nicotinic acetylcholine receptor agonisis
11/12/2003CN1455767A Substituted phenylcyclohexane carboxylic acid amides and use thereof
11/12/2003CN1455766A Novel 1,2-diphenylethene derivatives for treatment of immune diseases
11/12/2003CN1455691A Pharmaceutical compositions
11/12/2003CN1455682A Compositions for gene therapy of rheumatoid arthritis including gene encoding anti-angiogenic protein or parts thereof
11/12/2003CN1455679A Use of melagatran for manufacture of medicament for treatment of ischemic disorders
1 ... 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 ... 1564